Physician profile
Brian Thomas Ellis
NPI 1700046273
$2,742.36
in general payments reported to CMS, 2019-2025
31 companies · $563 in 2025
The $563 reported for 2025 was more than what 95% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $358 · 2021: $501 · 2022: $276 · 2023: $382 · 2024: $326 · 2025: $563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $404.99 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $403.86 | 2021-2025 | Qelbree |
| Corium, LLC | $263.51 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $236.34 | 2019-2024 | Jornay Pm |
| Sobi, INC | $208.01 | 2019-2023 | |
| Collegium Pharmaceutical, INC. | $174.98 | 2025 | Jornay Pm |
| Tris Pharma INC | $151.21 | 2019-2023 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $140.77 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $110.61 | 2019-2021 | |
| Kaleo, INC. | $103.29 | 2019-2022 | |
| Ucb, INC. | $63.75 | 2020-2021 | |
| Adlon Therapeutics L.P. | $54.61 | 2020-2021 | |
| Seqirus USA INC | $41.22 | 2022-2025 | Flucelvax |
| Astrazeneca Pharmaceuticals Lp | $41.01 | 2023-2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $39.26 | 2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $35.04 | 2024-2025 | Doc Band |
| Glaxosmithkline, LLC. | $28.28 | 2022-2023 | Bexsero |
| Ultragenyx Pharmaceutical INC. | $28.08 | 2021-2023 | |
| Verrica Pharmaceuticals INC. | $23.59 | 2024 | Ycanth |
| Mission Pharmacal Company | $18.75 | 2019 | |
| Stryker Corporation | $18.63 | 2021 | |
| Rhodes Pharmaceuticals L.P. | $18.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.14 | 2019 | |
| Alk-Abello, INC | $16.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.85 | 2024 | |
| Ironwood Pharmaceuticals, INC | $15.02 | 2024 | |
| Biomarin Pharmaceutical INC. | $14.93 | 2024 | Voxzogo 1.2mg |
| Galderma Laboratories, L.P. | $14.60 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.03 | 2025 | Relexxii |
| Sage Therapeutics, LLC | $13.88 | 2021 | |
| Genentech USA, INC. | $12.43 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.